نتایج جستجو برای: cll blood cancer

تعداد نتایج: 1557686  

Journal: :Journal of immunology 2011
Luca Bologna Elisa Gotti Massimiliano Manganini Alessandro Rambaldi Tamara Intermesoli Martino Introna Josée Golay

We analyzed in B-chronic lymphocytic leukemia (B-CLL) whole blood assays the activity of therapeutic mAbs alemtuzumab, rituximab, and type II glycoengineered anti-CD20 mAb GA101. Whole blood samples were treated with Abs, and death of CD19(+) B-CLL was measured by flow cytometry. Alemtuzumab efficiently lysed B-CLL targets with maximal lysis at 1-4 h (62%). In contrast, rituximab induced a more...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2008
Sivasubramanian Baskar Ka Yin Kwong Thomas Hofer Jessica M Levy Michael G Kennedy Elinor Lee Louis M Staudt Wyndham H Wilson Adrian Wiestner Christoph Rader

PURPOSE Gene expression profiling identified receptor tyrosine kinase ROR1, an embryonic protein involved in organogenesis, as a signature gene in B-cell chronic lymphocytic leukemia (B-CLL). To assess the suitability of ROR1 as a cell surface antigen for targeted therapy of B-CLL, we carried out a comprehensive analysis of ROR1 protein expression. EXPERIMENTAL DESIGN Peripheral blood mononuc...

Journal: :Blood 2001
A Migliazza F Bosch H Komatsu E Cayanis S Martinotti E Toniato E Guccione X Qu M Chien V V Murty G Gaidano G Inghirami P Zhang S Fischer S M Kalachikov J Russo I Edelman A Efstratiadis R Dalla-Favera

Deletions of the 13q14 chromosome region are associated with B-cell chronic lymphocytic leukemia (B-CLL) and several other types of cancer, suggesting the presence of a tumor suppressor gene. In previous studies the minimal region of deletion (MDR) was mapped to a less than 300-kilobase (kb) interval bordered by the markers 173a12-82 and 138G4/1.3R. For the identification of the putative tumor ...

Journal: :Molecular cancer research : MCR 2017
Hima V Vangapandu Ondrej Havranek Mary L Ayres Benny Abraham Kaipparettu Kumudha Balakrishnan William G Wierda Michael J Keating R Eric Davis Christine M Stellrecht Varsha Gandhi

Peripheral blood chronic lymphocytic leukemia (CLL) cells are quiescent but have active transcription and translation processes, suggesting that these lymphocytes are metabolically active. Based on this premise, the metabolic phenotype of CLL lymphocytes was investigated by evaluating the two intracellular ATP-generating pathways. Metabolic flux was assessed by measuring glycolysis as extracell...

Journal: :The Journal of clinical investigation 2017
Meixiao Long Kyle Beckwith Priscilla Do Bethany L Mundy Amber Gordon Amy M Lehman Kami J Maddocks Carolyn Cheney Jeffrey A Jones Joseph M Flynn Leslie A Andritsos Farrukh Awan Joseph A Fraietta Carl H June Marcela V Maus Jennifer A Woyach Michael A Caligiuri Amy J Johnson Natarajan Muthusamy John C Byrd

BACKGROUND Ibrutinib has been shown to have immunomodulatory effects by inhibiting Bruton's tyrosine kinase (BTK) and IL-2-inducible T cell kinase (ITK). The relative importance of inhibiting these 2 kinases has not been examined despite its relevance to immune-based therapies. METHODS Peripheral blood mononuclear cells from chronic lymphocytic leukemia (CLL) patients on clinical trials of ib...

2017
Gayane Manukyan Tomas Papajik Petr Gajdos Zuzana Mikulkova Renata Urbanova Gabriela Gabcova Milos Kudelka Peter Turcsányi Pavlina Ryznerova Vit Prochazka Eva Kriegova

A growing body of studies highlights involvement of neutrophils in cancer development and progression. Our aim was to assess the phenotypic and functional properties of circulating neutrophils from patients with chronic lymphocytic leukemia (CLL). The percentage of CD54+ and CD64+ neutrophils as well as CD54 expression on these cells were higher in CLL patients than in age-matched healthy contr...

Journal: :Blood 2013
Alan G Ramsay

In this issue of Blood, Dubovsky et al use novel methodology to identify lymphocyte cytosolic protein-1 (LCP1) as a putative tumor-associated antigen, Ag (TAA) that may play a critical role in regulating CLL cell homing to the leukemia niche. Their translational research approach further shows that kinase inhibitors (KIs) have the potential to block LCP1 activation, which raises the possibility...

Journal: :Blood 2009
Meike Vogler Michael Butterworth Aneela Majid Renata J Walewska Xiao-Ming Sun Martin J S Dyer Gerald M Cohen

ABT-737 and its orally active analog, ABT-263, are rationally designed inhibitors of BCL2 and BCL-X(L). ABT-263 shows promising activity in early phase 1 clinical trials in B-cell malignancies, particularly chronic lymphocytic leukemia (CLL). In vitro, peripheral blood CLL cells are extremely sensitive to ABT-737 (EC(50) approximately 7 nM), with rapid induction of apoptosis in all 60 patients ...

Journal: :Periodicum Biologorum 2022

Background and purpose: Cytotoxic effects of Ligustrum vulgare leaves on HeLa cervical tumor cells suggested that extracts should be investigated as potential anticancer agents. Therefore, we examined a antileukemic activity methanolic fruit two types leukemia cells, MOLT-4 JVM-13, lymphocytes isolated from the blood 33 chronic lymphocytic (CLL) patients mononuclear leukocytes 18 healthy indivi...

Journal: :Folia histochemica et cytobiologica 2009
Iwona Hus Jerzy Kawiak Grazyna Hoser Jacek Tabarkiewicz Sebastian Radej Anna Dmoszynska Jacek Rolinski

In the present study we investigated in vivo therapeutic potential of DCs vaccines in B-cell chronic lymphocytic leukemia (B-CLL). On the day 0 the SCID mice were intraperitoneally inoculated with peripheral blood mononuclear cells (PBMC) of B-CLL patients at a dose of 10-30 x 10(6) and left untreated (controls) or i.p. injected on the day 7 with 0.2 - 14.0 x 10(6) dendritic cells. DCs were gen...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید